Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Short-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) EBIAT (2016 - 2025)

Historic EBIAT for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$27.4 million.

  • Myriad Genetics' EBIAT fell 2398.19% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 24525.86%. This contributed to the annual value of -$127.3 million for FY2024, which is 5165.21% up from last year.
  • Latest data reveals that Myriad Genetics reported EBIAT of -$27.4 million as of Q3 2025, which was down 2398.19% from -$330.5 million recorded in Q2 2025.
  • Myriad Genetics' 5-year EBIAT high stood at $24.6 million for Q3 2021, and its period low was -$330.5 million during Q2 2025.
  • For the 5-year period, Myriad Genetics' EBIAT averaged around -$46.7 million, with its median value being -$31.2 million (2023).
  • In the last 5 years, Myriad Genetics' EBIAT surged by 26184.21% in 2021 and then crashed by 80054.5% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' EBIAT stood at -$7.6 million in 2021, then tumbled by 456.58% to -$42.3 million in 2022, then increased by 26.24% to -$31.2 million in 2023, then plummeted by 36.22% to -$42.5 million in 2024, then surged by 35.53% to -$27.4 million in 2025.
  • Its EBIAT stands at -$27.4 million for Q3 2025, versus -$330.5 million for Q2 2025 and -$100000.0 for Q1 2025.